RMD Form 4: Justin Leong Vests 5,462 Performance RSUs, Now Owns 27,180 Shares

Rhea-AI Filing Summary

Justin Leong, Chief Product Officer of ResMed Inc. (RMD), reported that 5,462 shares of company stock were acquired on 08/15/2025 upon the vesting of performance-based restricted stock units. These units were originally granted on 11/20/2024 and were certified as earned by the compensation committee when the performance metrics were met.

Following the transaction, Mr. Leong beneficially owns 27,180 shares. The reported acquisition shows a transaction code of A(1) with a reported price of $0, consistent with earned compensation rather than a market purchase.

Positive

• 5,462 shares were acquired through vesting, indicating performance metrics were met
• The reporting person now beneficially owns 27,180 shares, increasing insider alignment with shareholders
• Clear disclosure of grant date (11/20/2024) and vesting certification date (08/15/2025)

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider compensation-based share vesting increased the executive's stake; this is routine and non-dilutive to existing holdings.

The report documents the vesting of performance-based restricted stock units that converted to 5,462 shares on 08/15/2025, increasing the reporting person's holdings to 27,180 shares. The transaction code A(1) and a price of $0 indicate these shares were issued as earned compensation rather than purchased on the open market. For investors, this is a standard executive compensation event reflecting that pre-set performance targets were met and certified by the board's compensation committee.

Corporate Governance Expert

TL;DR: Vesting of performance RSUs signals goal attainment; disclosure is timely and follows Section 16 reporting requirements.

The filing shows the issuer certified performance metrics for RSUs granted 11/20/2024, resulting in vesting on 08/15/2025. The form is filed by one reporting person and is signed on 08/19/2025. This is a routine governance disclosure that confirms compensation committee action and transfers beneficial ownership to the executive. No derivative transactions or sales are reported.

Insider Trade Summary

Net Buyer: 5,462 shares

Net Buy 1 txn

Insider Leong Justin

Role Chief Product Officer

Type	Security	Shares	Price	Value
Grant/Award	ReMed Common Stock	5,462	$0.00	$0.00

Holdings After Transaction: ReMed Common Stock — 27,180 shares (Direct)

Footnotes (1)

1. F1. Represents performance-based restricted stock units granted on November 20, 2024. The shares were earned on August 15, 2025, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 08/19/2025 - 03:29 PM Learn about SEC filing dates

FAQ

What did Justin Leong report on Form 4 for RMD?

He reported the acquisition of 5,462 shares upon vesting of performance-based restricted stock units on 08/15/2025.

What is Justin Leong's role at ResMed and how many shares does he own after the transaction?

He is Chief Product Officer and beneficially owns 27,180 shares following the vested RSUs.

When were the performance-based RSUs granted and when were they certified as earned?

The RSUs were granted on 11/20/2024 and certified as earned on 08/15/2025.

What does the reported price of $0 signify on the Form 4?

A reported price of $0 indicates the shares were issued as compensation upon vesting rather than purchased.

Was this Form 4 filed by multiple reporting persons?

No. The form indicates it was filed by one reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leong Justin

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Product Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ReMed Common Stock	08/15/2025		A(1)		5,462	A	$0	27,180	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance-based restricted stock units granted on November 20, 2024. The shares were earned on August 15, 2025, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant.

	Justin Leong, Chief Product Officer	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.